Abstract
Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Current Enzyme Inhibition
Title:Aldose Reductase: A Multi-disease Target
Volume: 10 Issue: 1
Author(s): Jaiprakash N. Sangshetti, Rashmi S. Chouthe, Nikhil S. Sakle, Indrajeet Gonjari and Devanand B. Shinde
Affiliation:
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Abstract: Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Export Options
About this article
Cite this article as:
Sangshetti N. Jaiprakash, Chouthe S. Rashmi, Sakle S. Nikhil, Gonjari Indrajeet and Shinde B. Devanand, Aldose Reductase: A Multi-disease Target, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660007
DOI https://dx.doi.org/10.2174/15734080113096660007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis
Current Pharmaceutical Design Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer
Current Pharmaceutical Design Antibacterial and Antifungal Screening of Novel α-amino Acid Conjugated Bile Acid Derivatives
Current Bioactive Compounds Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Synthesis and Biological Evaluation of a Series of 2-(Substitutedphenyl) benzothiazoles
Medicinal Chemistry Boron-Containing Compounds as Preventive and Chemotherapeutic Agents for Cancer
Anti-Cancer Agents in Medicinal Chemistry